<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281019</url>
  </required_header>
  <id_info>
    <org_study_id>90947376</org_study_id>
    <nct_id>NCT02281019</nct_id>
  </id_info>
  <brief_title>SpyGlass AMEA Registry</brief_title>
  <official_title>Clinical Registry of Cholangioscopy Using the SpyGlass™ Direct Visualization System (DVS) Throughout the AMEA (Asia, Middle-East, Africa) Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to document indications for cholangioscopy and clinical utility
      of the SpyGlass Direct Visualization System throughout the AMEA (Asia, Middle-East, Africa)
      region when used per standard of practice.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Procedural success for indeterminate strictures or undefined filling defects</measure>
    <time_frame>Procedure - the average expected duration of the procedure is 1.5 hours</time_frame>
    <description>For indeterminate strictures or undefined filling defects cases procedural success is defined as 1) ability to visualize stricture or defect, and 2) ability to provide visual impression of malignancy, and 3) when applicable, ability to obtain SpyBite biopsy adequate for histology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural success for biliary stone cases</measure>
    <time_frame>Procedure - the average expected duration of the procedure is 1.5 hours</time_frame>
    <description>For biliary stone cases procedural success is defined as 1) ability to visualize the stone(s), and 2) ability to successfully initiate stone fragmentation, and 3) ability to achieve stone clearance in one or more SpyGlass procedures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural success for other indications</measure>
    <time_frame>Procedure - the average expected duration of the procedure is 1.5 hours</time_frame>
    <description>For other indications procedural success is defined as ability to establish diagnosis and /or complete therapy in the following categories: 1) pre-operative assessment of extent of peri-ampullary and biliary tumors, 2) selective guidewire placement, 3) assessment of unexplained hemobilia, 4) assessment of portal biliopathy, 5) assessment of intraductal biliary ablation therapy, 6) extraction of migrated stents, or 7) other.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of serious adverse events (SAEs) related to the SpyGlass devices and/or the SpyGlass procedure</measure>
    <time_frame>Procedure from enrollment through the 72 Hour Post Procedure Follow-up Visit</time_frame>
    <description>Evaluation of serious adverse events (SAEs) related to the SpyGlass devices and/or the SpyGlass procedure from enrollment through the 72 Hour Post Procedure Follow-up Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of SpyGlass procedure on suspected diagnosis based on prior ERCP</measure>
    <time_frame>Procedure - the average expected duration of the procedure is 1.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of impact of use of antibiotics on incidence of SAEs related to the device and/or procedure.</measure>
    <time_frame>Procedure - the average expected duration of the procedure is 1.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients undergoing SpyBite biopsy: correlation between number of biopsies and conclusive histopathology of SpyBite biopsies.</measure>
    <time_frame>Procedure to 6 months</time_frame>
    <description>Assessment Detail:
Endpoint determined for all patients in whom SpyBite biopsy was taken and observed image features were reported.
Observed image features include the following categories: None, Growth, Stricture, Hyperplasia, Ulceration, Mass, Dilated tortuous vessels, Papillary or villous projections, Intraductal nodules, Mucus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients undergoing stone management: number of SpyGlass procedures needed to reach stone clearance.</measure>
    <time_frame>Procedure - the average expected duration of the procedure is 1.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients undergoing stone management: correlation between stone size and ability to reach stone clearance in one SpyGlass session.</measure>
    <time_frame>Procedure - the average expected duration of the procedure is 1.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients undergoing stone management: incidence of visualization of stones not suspected during previous ERCP.</measure>
    <time_frame>Procedure - the average expected duration of the procedure is 1.5 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">526</enrollment>
  <condition>Biliary Stricture</condition>
  <condition>Biliary Obstruction Due to Common Bile Duct Stone</condition>
  <condition>Periampullary Tumor</condition>
  <condition>Hemobilia</condition>
  <arm_group>
    <arm_group_label>Indeterminate strictures or undefined filling defects</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliary stone cases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Other indications</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERCP (Endoscopic Retrograde Cholangiopancreatography)</intervention_name>
    <description>ERCP procedure will be performed to visualize bile ducts.</description>
    <arm_group_label>Indeterminate strictures or undefined filling defects</arm_group_label>
    <arm_group_label>Biliary stone cases</arm_group_label>
    <arm_group_label>Other indications</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpyGlass DVS and SpyGlass DS</intervention_name>
    <description>Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed</description>
    <arm_group_label>Indeterminate strictures or undefined filling defects</arm_group_label>
    <arm_group_label>Biliary stone cases</arm_group_label>
    <arm_group_label>Other indications</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue acquisition in the bile ducts
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients seen at an investigational site during the enrollment period

          -  Presenting with an indication for cholangioscopy, or

          -  Presenting with a possible indication for cholangioscopy to be determined during the
             ERCP procedure immediately preceding the SpyGlass procedure.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older.

          -  Willing and able to provide written informed consent to participate in the study.

          -  Willing and able to comply with the study procedures.

          -  Indicated for ERCP and cholangioscopy or indicated for ERCP with suspected need for
             cholangioscopy.

        Exclusion Criteria:

          -  Endoscopic techniques are contraindicated.

          -  ERCP is contraindicated

          -  A medical condition that warrants the use of the device outside of the indication for
             use.

          -  Requirement for anticoagulation that cannot be safely stopped at least 7 days prior to
             the procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedict Devereaux</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brisbane and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Lau</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Wales Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randhir Sud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Digestive &amp; Hepatobiliary Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saad Niaz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Civil Hospital- Karachi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdulrahman Aljebreen</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Khalid University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ang Tiing Leong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changi General Hospital Pte Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorg Reichenberger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Netcare Unitas Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Moon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soon Chun Hyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rungsun Rerknimitr</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Chulalongkorn Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ichiro Yasuda</last_name>
    <role>Principal Investigator</role>
    <affiliation>Teikyo University Mizonokuchi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur J. Kaffes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Prince Alfred Hospital, Sydney, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nam Q. Nguyen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Adelaide Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amit Maydeo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baldota Institute of Digestive Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohan Ramchandani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asian Institute of Gastroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahesh Goenka</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apollo Gleneagles Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor R. Kochhar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Postgraduate Institute of Medical Education &amp; Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takao Itoi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokyo Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masayuki Kitano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kinki University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong K. Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dongwan Seo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Newtown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Queensland</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education &amp; Research</name>
      <address>
        <city>Chandigarh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medanta -The Medicity Institute of Digestive &amp; Hepatobiliary Sciences</name>
      <address>
        <city>Gurgaon</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Institute of Gastroenterology</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baldota Institute of Digestive Sciences</name>
      <address>
        <city>Parel</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneagles Hospitals Kolkata</name>
      <address>
        <city>West Bengal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Mizonokuchi Hospital</name>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University School of Medicine</name>
      <address>
        <city>Osaka-sayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Civil Hospital- Karachi</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Khalid University Hospital</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital Pte Ltd.</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netcare Unitas Hospital</name>
      <address>
        <city>Centurion</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Pakistan</country>
    <country>Saudi Arabia</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2014</study_first_posted>
  <last_update_submitted>May 26, 2016</last_update_submitted>
  <last_update_submitted_qc>May 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemobilia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

